Serum sclerostin levels in renal cell carcinoma patients with bone metastases

Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wibmer, C., Amrein, K., Fahrleitner-Pammer, A., Gilg, M. M., Berghold, A., Hutterer, G. C., Maurer-Ertl, W., Gerger, A., Leithner, A., Pichler, M., Szkandera, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036091/
https://www.ncbi.nlm.nih.gov/pubmed/27666393
http://dx.doi.org/10.1038/srep33551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036091/
https://www.ncbi.nlm.nih.gov/pubmed/27666393
http://dx.doi.org/10.1038/srep33551

Ejemplares similares